Belgians and Luxembourgians with childhood GHD: adult outcomes and follow-up

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational/interventional study examines adults who were treated with recombinant human growth hormone during childhood for CO-GHD in Belgium and Luxembourg. The primary aim is to measure how many continue regular medical follow-up and whether they are still receiving rhGH as adults, using a questionnaire. Secondary goals include assessing follow-up regularity, treatment adherence, comorbidities, health status, lifestyle and quality of life, as well as profiling metabolic factors like BMI, glucose, and lipids in consenting participants. Data will be described by treatment adherence and CO-GHD etiology/phenotypes. Participants must be 18 or older, previously diagnosed with CO-GHD, registered in the BELGROW registry, and stopped rhGH after 2011 with persistent GHD at growth end.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> or = 18 years
* Diagnosed with child-hood onset growth hormone deficiency (CO-GHD) (no exclusion criteria: isolated or multiple GHD, idiopathic or organic, severe or partial)
* Registered in the BELGROW registry (informed consent at the time of inclusion in registry)
* Stopped treatment with rhGH for growth after 2011
* Persistent GHD at the end of growth

Exclusion Criteria:

* No exclusion criteria

Where it's running

• Cliniques Universitaires Saint-Luc
  Brussels, Woluwe-saint-lambert, Belgium Recruiting

Study contacts

• Principal investigator: Philippe Lysy, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Study coordinator: Philippe Lysy, MD, PhD
• Email: philippe.lysy@saintluc.uclouvain.be
• Phone: 02 7641370

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding growth hormone deficiency after a brain injury in adults

  This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

  Recruiting University of Calgary · Calgary, Alberta and 1 other locations · NCT07795736

• Easy-to-Use Growth Hormone Deficiency Treatment: A New Injectable for Adults

  This phase 2b-like study tests whether a new injectable called Inpegsomatropin can be safely given in multiple escalating doses to adults with growth hormone deficiency, to see if it helps them and how it behaves in the body.

  Recruiting at 6 sites Phase 2 Xiamen Amoytop Biotech Co., Ltd. · Beijing and 5 other locations · NCT07551804

• GenSci134 in healthy adults and adults with growth hormone deficiency

  This Phase 1 trial will test single and multiple subcutaneous doses of GenSci134 in healthy adults and single doses in adults with growth hormone deficiency to check safety, tolerability, pharmacokinetics, pharmacodynamics, and immune response.

  Recruiting Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07016802

• Observational study on the effectiveness and safety of SKYTROFA for growth hormone deficiency

  This study is testing how well and safely SKYTROFA works for people with growth hormone deficiency by looking at their experiences during regular treatment.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05820672

• Long-term safety assessment of lonapegsomatropin in children with growth hormone deficiency

  This study looks at the long-term safety of lonapegsomatropin in children with growth hormone deficiency who are already being treated with it.

  Recruiting at 27 sites Ascendis Pharma A/S · Phoenix, Arizona and 26 other locations · NCT05775523

• Effects of growth hormone and liraglutide on appetite regulation

  This study is testing if growth hormone and liraglutide can change appetite-related hormones in healthy adults and those with growth hormone deficiency to see how they affect weight and energy use.

  Recruiting Phase 4 Columbia University · New York, New York · NCT05681299

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.